How to profit from the obesity epidemic

Companies in diabetes treatment, weight management and weight-loss drugs could see see huge growth.

By Traders Reserve Nov 7, 2013 1:13PM

File photo of packs of Weight Watchers sliced meats (© Isopix/Rex Features)By Karen Riccio
More than a third of adults in the U.S. are considered obese, according to the Centers for Disease Control and Prevention. A report by the American Journal of Preventive Medicine says that by 2030, that figure could grow to 42%.

Add another 18% of children ages 6-19 considered obese, and we're talking about a multibillion-dollar epidemic.
That means a huge opportunity for investors in the health care sector.

Here's how. At least three industries, and key stocks in each, stand to benefit from the long-term fight against obesity: healthcare (testing/treatment of diabetes, heart disease, hypertension), weight management (dietary programs and physical activity); and pharmaceuticals (the so-called magic bullet).
This market is bigger than many realize. The term "obese" may bring to mind the 500-pound talk show guest, but that’s not the case. It only takes an extra 30 pounds to be classified as obese and to garner health risks. It ultimately comes down to having a body mass index (BMI) of 30 or higher, meaning you have too much fat.


30 million affected by diabetes

Obesity contributes to increased rates of more than 30 serious diseases. The most common, Type 2 diabetes, affects about 30 million people and is linked to excess fat and a sedentary lifestyle.

Eric Schlosser, author of "Fast Food Nation," states that "the annual health care costs in the United States stemming from obesity are approaching $240 billion,” or more than 20% of this country’s total medical bill. If the rate of childhood obesity stays constant, that figure could grow to $957 billion by 2030.

The sheer number of obese and the health care markets that cater to them mean a number of angles in for investors. Here are key industries and leading stocks:

The business of treating diabetes

The major manufacturers of insulin, the main treatment for diabetes, are Novo Nordisk (NVO), Sanofi-Aventis (SNY) and Eli Lilly (LLY). Global sales related to diabetes are a staggering $15.4 billion annually, increasing 400% since 2000.

It is predicted that by 2050, 20% to 30% of the U.S. population will have diabetes, mostly with obese-driven Type 2. United Healthcare estimates that Americans will spend $3.4 trillion over the next 10 years in diabetes-related costs.

Invested in weight management
The weight-management industry generates $59 billion in revenue annually in the U.S. alone. You might say that the potential loss of pounds by customers of Weight Watchers  International (WTW), NutriSystem (NTRI) and Nestle (NSRGY) (which owns Jenny Craig and Lean Cuisine) could translate into healthy gains for investors.

Weight Watchers has focused on group support, sustainable food plans and behavior modification for 50 years. In 2012, consumers spent $5 billion on Weight Watchers’ branded products and services.


As you would expect, an economic slowdown in 2009 saw  Weight Watchers' net revenue fall 8.9%. However, from fiscal 2008-2012, revenues compounded at an annual growth rate of 4.4% and shareholder equity rose 30%. Weight Watchers will likely remain one of the go-to companies for people needing to shed pounds.

Drug makers and the obesity market
When it comes to the drug industry, three heavyweights basically corner the market for obesity treatments: Xenical from Roche (RHHBY), Belviq from Arena Pharmaceuticals (ARNA) and Qsymia, a product of Vivus (VVUS).

Not expected to gain FDA approval until 2014 or 2015, Contrave from Orexigen (OREX) may eventually give the others a run for their money, but not in the short-term.

Unfortunately, no matter how we choose to prevent and treat obesity, the real battle has just begun. Good, bad or otherwise, so has the uptrend in related stocks. 

More from Traders Reserve




Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123 rated 1
262 rated 2
480 rated 3
651 rated 4
649 rated 5
629 rated 6
616 rated 7
496 rated 8
346 rated 9
111 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.